Skip to main content

Rezurock Dosage

Generic name: BELUMOSUDIL 200mg
Dosage form: tablet
Drug class: Selective immunosuppressants

Medically reviewed by Drugs.com. Last updated on Jan 8, 2025.

Recommended Dosage

The recommended dose of REZUROCK is 200 mg given orally once daily until progression of chronic GVHD that requires new systemic therapy.

Instruct the patient on the following:

  • Swallow REZUROCK tablets whole. Do not cut, crush, or chew tablets.
  • Take REZUROCK with a meal at approximately the same time each day.
  • If a dose of REZUROCK is missed, instruct the patient to not take extra doses to make up the missed dose.

Treatment with REZUROCK has not been studied in patients with pre-existing severe renal impairment. For patients with pre-existing severe renal impairment, consider the risks and potential benefits before initiating treatment with REZUROCK.

Dosage Modifications for Adverse Reactions

Monitor total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) at least monthly.

Modify the REZUROCK dosage for adverse reactions as per Table 1.

Table 1: Recommended Dosage Modifications for REZUROCK for Adverse Reactions
Adverse Reaction Severity* REZUROCK Dosage Modifications
*
Based on CTCAE v 4.03
Hepatotoxicity Grade 3 AST or ALT (5× to 20× ULN) or Grade 2 bilirubin (1.5× to 3× ULN) Hold REZUROCK until recovery of bilirubin, AST and ALT to Grade 0–1, then resume REZUROCK at the recommended dose.
Grade 4 AST or ALT (more than 20× ULN) or Grade ≥3 bilirubin (more than 3× ULN) Discontinue REZUROCK permanently.
Other adverse reactions Grade 3 Hold REZUROCK until recovery to Grade 0–1, then resume REZUROCK at the recommended dose level.
Grade 4 Discontinue REZUROCK permanently.

Dosage Modification Due to Drug Interactions

Strong CYP3A Inducers

Increase the dosage of REZUROCK to 200 mg twice daily when coadministered with strong CYP3A inducers.

Proton Pump Inhibitors

Increase the dosage of REZUROCK to 200 mg twice daily when coadministered with proton pump inhibitors.

Recommended Dosage in Patients with Hepatic Impairment

Avoid use in patients with moderate hepatic impairment (Child-Pugh B) or severe hepatic impairment (Child-Pugh C) without liver GVHD.

No dosage adjustment is recommended when administering REZUROCK to patients with mild hepatic impairment.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer